

CLINICAL PRACTICE

Management of Newly Diagnosed HIV Infection

Scott M. Hammer, M.D.

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.

As part of a routine examination for insurance coverage, a 25-year-old previously healthy woman is found to have a positive test for human immunodeficiency virus type 1 (HIV-1) antibody. Heterosexual contact is her only risk factor for HIV acquisition. She is asymptomatic and has a normal physical examination. The results of hematology and other routine laboratory tests are normal. Her CD4 cell count is 325 cells per cubic millimeter, and her plasma HIV-1 RNA level is 60,000 copies per milliliter (both confirmed on repeated testing). How should her case be managed?

THE CLINICAL PROBLEM

From the Division of Infectious Diseases, Columbia University Medical Center, New York. Address reprint requests to Dr. Hammer at the Division of Infectious Diseases, Columbia University Medical Center, 630 W. 168th St., PH 8 West, Room 876, New York, NY 10032, or at smh48@columbia.edu.

N Engl J Med 2005;353:1702-10.
Copyright © 2005 Massachusetts Medical Society.

In the United States, it is estimated that 900,000 to 1 million persons are infected with HIV-1. One quarter to one third of these persons do not know their infection status, thus jeopardizing their own care and putting others at risk through transmission that might be prevented with counseling, behavior modification, and potentially, antiretroviral therapy.¹ The number of new cases of acquired immunodeficiency syndrome (AIDS) reported each year in the United States has been stable, at approximately 40,000, but the incidence of HIV-1 infection and other sexually transmitted infections has increased in certain at-risk populations, such as men who have sex with men. Blacks, Hispanics, and women are disproportionately represented among persons with HIV-1 infection, AIDS, or both.²

The era of potent antiretroviral therapy, which began in 1996, has resulted in marked reductions in the rates of illness and death due to HIV-1 infection in the developed world and has led to the management of HIV-1 infection as a chronic disease, with life expectancies after diagnosis now measured in decades.³

STRATEGIES AND EVIDENCE

SCREENING FOR HIV INFECTION

When evaluating patients, physicians should routinely consider the possibility of HIV infection. Screening is relevant not only in patients with opportunistic infections or HIV-associated cancers but also in patients who have severe illnesses, such as pneumococcal bacteremia, that are seen with increased frequency in the setting of HIV infection; those who have illnesses that may indicate a risk of HIV acquisition (e.g., sexually transmitted infections, such as syphilis, gonorrhea, *Chlamydia trachomatis* infection, and genital herpes simplex virus infection) or subtle immunodeficiency (e.g., herpes zoster, oral candidiasis, and oral hairy leukoplakia); and those who report high-risk behavior (e.g., unprotected sex and the use of illicit drugs) when presenting for care for any reason. Recently, the Centers for Disease Control and Prevention (CDC) launched a pro-

gram to promote HIV antibody testing as a routine element of medical care.⁴ The goals of routine screening are to better define the true prevalence of infection in the United States, to bring persons infected with HIV-1 into care, to offer opportunities for prevention of the secondary spread of infection, and in persons found to be HIV-seronegative, to provide the opportunity for counseling in order to reduce the risk of virus acquisition. Recent reports have suggested that screening for HIV in the general U.S. adult population, in which there is a low prevalence of HIV-1 infection (1 percent or less), could be cost-effective whether performed once or repeated every three to five years.^{5,6}

TESTING AND COUNSELING

Making HIV testing more widely available requires having adequate services in place to ensure proper counseling before and after testing, with fully informed consent from patients. Approval by the Food and Drug Administration of rapid HIV antibody tests, which can provide results in as little as 20 minutes, has improved the efficiency of point-of-care testing. The sensitivity and specificity of the approved rapid HIV antibody kits are similar to those of standard serum enzyme-linked immunosorbent assay tests⁷; confirmation of the result by another test, such as a Western blot analysis, is still required. Rapid testing is useful in several circumstances, such as at the time of delivery for pregnant women who have not received prenatal care, at sexually transmitted disease clinics, and at emergency departments, urgent care centers, and in-hospital settings, where immediate knowledge of patient status will affect decisions regarding care and follow-up. Appropriate counseling is necessary for patients who test positive, to address issues such as stigma and the fear of disclosure of one's HIV status; the need to inform previous or current sexual partners who may have been put at risk; HIV testing of children who may have been conceived after the patient became infected with HIV; strict adherence to safe-sex practices; and avoidance of drugs such as methamphetamines that may disinhibit behavior.⁸

The use of condoms should be emphasized as an effective means to prevent sexual transmission of HIV-1 as well as to prevent the acquisition of other sexually transmitted infections, including superinfection with another strain of HIV-1.⁹ The effectiveness of condoms in the reduction of HIV-1 transmission has been estimated at 87 percent (range, 60 to 96).¹⁰ Counseling should underscore

the fact that, although it is a lifelong problem, HIV disease can be managed successfully in the vast majority of persons. Patients should be encouraged to reveal their HIV status to trusted and supportive family members and friends, and they should be offered professional counseling.

EVALUATION OF THE PATIENT

Patients with a new diagnosis of HIV-1 infection should provide a complete history and undergo physical examination to determine whether there are any clinical manifestations of infection. Given the projected long-term management of HIV disease, the evaluation should also include screening and counseling for health-maintenance issues not related to HIV and recognition of conditions that may interact with the management of HIV, particularly with respect to potential interactions of other drugs with antiretroviral agents and cardiovascular risks that may be increased by some antiretroviral drugs.¹¹ Recommended laboratory tests are summarized in Table 1. It is essential to determine CD4 cell counts and plasma HIV-1 RNA levels (i.e., the viral load), both to establish the prognosis and to inform the decision regarding whether to start antiretroviral therapy (Table 2). Testing for resistance to drugs used in the treatment of HIV infection should also be considered, since primary acquisition of drug-resistant HIV strains is a risk.^{8,12,15-17} Once the diagnosis of HIV infection is confirmed, referral to a specialist in HIV care is appropriate.¹⁹

PROPHYLAXIS AGAINST OPPORTUNISTIC INFECTIONS

Manifestations of HIV-related opportunistic disease can occur at virtually any level of CD4 cell count, but the incidence of serious and potentially life-threatening infections increases dramatically as the CD4 cell count drops below 200 cells per cubic millimeter. CD4 thresholds of 200, 100, and 50 cells per cubic millimeter have been established as levels that demarcate the risks of *Pneumocystis jirovecii*, *Toxoplasma gondii*, and *Mycobacterium avium* complex infections, respectively, and are indications for prophylaxis²⁰⁻²⁵ (Table 3). Randomized trials indicate that the risks of these infections can be reduced by 50 to 80 percent or more with appropriate prophylaxis.^{22,23}

INITIATION OF ANTIRETROVIRAL THERAPY

Consensus guidelines support the strategy of offering antiretroviral therapy to anyone with HIV-

Table 1. General Laboratory Tests Recommended for Persons with Newly Diagnosed HIV Infection.*

| Test | Comment |
|---|--|
| Complete blood count | Anemia may contraindicate use of zidovudine. |
| Electrolytes, blood urea nitrogen, creatinine, fasting blood sugar | Abnormal renal function may contraindicate use of tenofovir or indicate need for adjustment of renally excreted nucleoside or nucleotide analogues; baseline presence of diabetes may contraindicate use of protease inhibitors, which can cause insulin resistance. |
| Bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase | Indinavir and atazanavir can elevate indirect bilirubin levels. Abnormal liver-enzyme levels may indicate need for further workup, may influence choice of antiretroviral agents, which carry risk of hepatotoxicity, or both. |
| Creatine kinase | Elevated value may reflect, most commonly, exercise or underlying HIV myopathy; a baseline value is helpful, to monitor zidovudine therapy, which may cause drug-induced myopathy. |
| Amylase, lipase | Baseline values may be helpful for making decisions regarding use of drugs (e.g., didanosine) that carry risk of pancreatitis. |
| Fasting lipid profile | Abnormal baseline values may indicate need for dietary therapy, drug therapy, or both, or possible avoidance of therapy with certain protease inhibitors. |
| Serologic tests for syphilis (e.g., plasma reagin test) | Evidence of past or recent exposure requires treatment unless there is documentation of adequate course of treatment. |
| Serologic tests for hepatitis A, B, and C viruses | If negative, counseling to prevent acquisition of all three viruses and vaccination for hepatitis A and B viruses are indicated. If active infection with hepatitis B or C virus, or both, is present, decision should be made about specific treatment and its relation to antiretroviral therapy. |
| Toxoplasmosis titer | If negative, counseling to prevent acquisition of <i>Toxoplasma gondii</i> (including avoidance of undercooked meat and of cat feces) is indicated. If positive, and CD4 cell count is <100 per mm ³ , primary prophylaxis is indicated. (Patients with very advanced HIV infection may lose antibody to <i>T. gondii</i> .) |
| CMV titer | If negative, counseling is indicated to prevent acquisition of virus through intimate contact or blood transfusion. If blood products are needed, screening should be considered, to prevent CMV acquisition. Whether there is a routine need for this test is debatable, given the decreased incidence of CMV-associated disease with the use of potent antiretroviral therapy. |
| Cervical Papanicolaou smear | Important, given the prevalence of HPV infection and increased risk of cervical neoplasia. |
| Anal screening for HPV | No consensus recommendation exists, but consideration of Papanicolaou smear, HPV DNA test, or both, is reasonable, given associated risk of anal carcinoma. |
| Tuberculin skin test | If positive (induration ≥5 mm) and active tuberculosis is ruled out, isoniazid therapy for nine months should be considered. |
| Electrocardiography | Baseline tracing may be important, given potential for increased cardiovascular risk associated with antiretroviral therapy (especially some protease inhibitors). Atazanavir can prolong PR interval. |
| Chest radiography | Important to consider obtaining a baseline film, owing to numerous HIV-related complications that can manifest as pulmonary disease. |

* Because of potential past exposure to pathogens that may reactivate with immunosuppression, additional baseline laboratory screening tests to consider in persons with newly diagnosed HIV infection may include titers for *Histoplasma capsulatum*, *Coccidioides immitis*, and *Blastomyces dermatitidis*. If these tests are negative, counseling (e.g., regarding travel and recreation) to avoid acquisition should be considered. If positive, the awareness that risk increases as immunosuppression worsens may help in the management of HIV infection. In the United States, histoplasmosis is endemic in the Mississippi River Valley, Puerto Rico, and foci in other parts of the country; coccidioidomycosis is endemic in central California and the Southwest; and blastomycosis is endemic in the Southeast. Blastomycosis is relatively rare in patients with AIDS, so the role of testing for this infection is particularly uncertain. Stool examination for *Strongyloides stercoralis* also should be considered in patients with a history of travel to or residence in tropical or semitropical areas. If positive, treatment is indicated to avoid the potential for future development of hyperinfection syndrome with advanced immunosuppression. However, routine testing cannot be recommended on the basis of available data. CMV denotes cytomegalovirus, and HPV human papillomavirus. Data are from the Department of Health and Human Services¹² and Aberg et al.¹³

Table 2. HIV-Specific Baseline Tests for Persons with Newly Diagnosed HIV Infection.*

| Test | Comment |
|--|--|
| CD4 cell count | Critical for determining patient's disease stage and short-term and mid-term risk of opportunistic complication, and for assessing need to recommend prophylaxis against opportunistic infections and initiation of antiretroviral therapy. Two values, obtained one to four weeks apart, should be considered, to establish firm baseline value. |
| Plasma HIV-1 RNA | Critical for determining viral burden, assessing potential rate of loss of CD4 cells, and evaluating mid-term and long-term risk of opportunistic complication. Adjunctive to CD4 cell count in assessing need to recommend antiretroviral therapy. Two values, obtained one to four weeks apart, should be considered, to establish firm baseline value. Best quantitative laboratory marker to monitor success of antiretroviral therapy. |
| Genotype test for antiretroviral drug resistance | Helpful in choice of initial therapy in areas where prevalence of drug-resistant HIV is >5%, although uniform surveillance data are not available. Should definitely be considered for persons thought to have acquired infection relatively recently (i.e., within the previous three years) and increasingly should be considered for all patients with established infection as part of baseline evaluation. (Persistence of drug-resistant variants of HIV after primary acquisition is dependent on fitness of mutant virus and evolution of viral diversity after infection. Some mutations may persist for months to years [e.g., K103N], and others, which are less fit, may recede to a small fraction of the overall viral population, only to reemerge with therapy.) |

* Data are from the Department of Health and Human Services,¹² Mellors et al.,¹⁴ Hirsch et al.,¹⁵ Little et al.,¹⁶ Yeni et al.,¹⁷ and Egger et al.¹⁸

related symptoms or signs.^{12,17} Although data from randomized trials are not sufficient to guide the decision regarding when to initiate antiretroviral therapy in asymptomatic persons, several observational cohort studies have provided useful information.^{18,26-33} The near-uniform finding that disease progression and mortality are significantly worse among patients whose treatment is delayed until the CD4 cell count is less than 200 per cubic millimeter^{18,27-34} indicates that antiretroviral therapy should be initiated when the CD4 cell count is above this level. Persons who present initially with CD4 cell counts of less than 200 cells per cubic millimeter should be offered treatment as soon as the baseline evaluation and initial counseling regarding drug adherence are completed. Persons with CD4 cell counts of more than 350 per cubic millimeter generally can be observed without therapy, on the basis of data showing similar outcomes with and without therapy among patients with CD4 cell counts in this range³⁰; exceptions are patients whose plasma HIV-1 RNA level is more than 100,000 copies per milliliter,¹⁸ since this level is associated with an increased risk of progression to AIDS that is independent of the CD4 cell count. In persons who are being followed without therapy, a rapid decline in the CD4 cell count (i.e., a decline of more than 100 cells per cubic millimeter per year) may also be factored into the decision regarding when to initiate therapy.¹⁷

For persons with CD4 cell counts between 200

and 350 per cubic millimeter, the recommendation to start therapy should be considered on an individual basis. In practical terms, initiating antiretroviral therapy when the CD4 cell count is at the upper end of this range is reasonable if the patient is willing and committed. This strategy provides a buffer by which to avoid a drop in the CD4 cell count to less than 200 cells per cubic millimeter and may also prevent symptomatic disease, which can occur above this cutoff. One study has suggested that a level within the range of 200 to 350 cells per cubic millimeter, and specifically of about 275 cells per cubic millimeter, may be a threshold below which progression to AIDS is more likely.³¹

TREATMENT REGIMEN

Combination antiretroviral therapy should suppress the plasma HIV-1 RNA titer to less than 50 copies per milliliter. This target correlates with durability of viral suppression, prevention of the emergence of drug resistance, and immunologic and clinical benefit. Viral evolution and genotypic changes in the virus over time due to errors in reverse transcription, selective drug or immune pressure, or both may still occur in HIV reservoirs at this level of suppression; however, when a change does occur, it typically involves the gene encoding the HIV envelope (not the reverse transcriptase and protease genes), thus preserving susceptibility to the major classes of HIV enzyme inhibitors.³⁵⁻⁴⁰

There are now 21 antiretroviral agents, repre-

Table 3. Primary Prophylaxis against Major Infectious Pathogens That Can Cause Complications in the Patient with Newly Diagnosed HIV Infection.*

| Pathogen | CD4 Count (cells/mm ³) | Agent | Major Side Effects | Alternative Agent |
|------------------------------------|---|---|---|--|
| <i>Pneumocystis jiroveci</i> | <200 | Trimethoprim–sulfamethoxazole, 160 mg and 800 mg, once daily | Rash, fever, abnormal liver-enzyme levels, hematologic toxicity, pancreatitis | Dapsone, 100 mg once daily (if G6PD level is normal) |
| <i>Toxoplasma gondii</i> | <100 | Trimethoprim–sulfamethoxazole, 160 mg and 800 mg, once daily | Rash, fever, abnormal liver-enzyme levels, hematologic toxicity, pancreatitis | Dapsone, 200 mg, plus pyrimethamine, 75 mg, plus leucovorin, 25 mg, once weekly |
| <i>Mycobacterium avium</i> complex | <50 | Azithromycin, 1200 mg, once weekly | Gastrointestinal symptoms | Clarithromycin, 500 mg, twice daily |
| <i>M. tuberculosis</i> | Any (tuberculin skin test, positive at induration of ≥5 mm, or history of significant exposure) | Isoniazid, 300 mg, once daily (with pyridoxine, 50 mg, once daily) for 9 months; Active tuberculosis should be ruled out before initiating treatment with isoniazid | Abnormal liver-enzyme levels, peripheral neuropathy | Risks and benefits of alternative prophylactic regimens should be carefully evaluated on an individual basis |
| <i>Streptococcus pneumoniae</i> | Any, but response to vaccine is better in persons with >200 | 23-valent pneumococcal polysaccharide vaccine; need for revaccination after 5 years has not been established | Local reaction at site of injection; transient systemic symptoms | |
| Influenza virus | Any | Inactivated influenza vaccine once yearly | Local reaction at site of injection; transient systemic symptoms | Oseltamivir, 75 mg, once daily during outbreak if not protected by vaccination |
| Hepatitis A virus | Any | Hepatitis A vaccine | Local reaction at site of injection | Combined hepatitis A and B vaccine now available |
| Hepatitis B virus | Any | Hepatitis B vaccine | Local reaction at site of injection; transient systemic symptoms | Combined hepatitis A and B vaccine now available |

* G6PD denotes glucose-6-phosphate dehydrogenase. Data are from the CDC²⁴ and the U.S. Public Health Service.²⁵

senting five drug classes, and five fixed-dose combinations approved in the United States for the treatment of HIV-1 infection. Randomized trials of triple-drug combination regimens in patients who have not previously received treatment have shown that regimens that include nonnucleoside reverse-transcriptase inhibitors and those based on ritonavir-boosted protease inhibitors result in viral suppression to a level of less than 50 copies per milliliter in more than 60 percent of patients and raise CD4 cell counts by approximately 175 to 200 per cubic millimeter after 48 weeks of treatment.⁴¹ Intolerance of or an inadequate response to any one regimen frequently requires a change to an alternative regimen; assessment of drug adherence should always be the first step when considering why a response to therapy is suboptimal.

The regimens based on nonnucleoside reverse-transcriptase inhibitors that are currently being prescribed involve either efavirenz or nevirapine in combination with either two nucleoside ana-

logue reverse-transcriptase inhibitors or a nucleoside analogue and a nucleotide analogue reverse-transcriptase inhibitor (Table 4). Of the nonnucleoside reverse-transcriptase inhibitors, efavirenz is generally favored because of its better toxicity profile and once-daily administration. Efavirenz should be avoided in pregnant women, however, because of its potential teratogenic effects. Nevirapine can cause serious hepatotoxicity and confers a higher risk of severe rash than does efavirenz.

The most commonly used dual nucleoside or nucleoside–nucleotide component is lamivudine or emtricitabine combined with either zidovudine or tenofovir disoproxil fumarate (Table 4). In a randomized trial, the combination of efavirenz and tenofovir–emtricitabine was superior to that of efavirenz and zidovudine–lamivudine; the proportions of patients with a plasma HIV-1 RNA level of less than 50 copies per milliliter were 77 percent and 69 percent, respectively, with increases in the CD4 cell count of 189 and 158 cells per cubic millimeter,

Table 4. Selected Initial Antiretroviral Regimens and Components for HIV-Infected Patients with Drug-Susceptible Virus.*

| A Nonnucleoside Reverse-Transcriptase Inhibitor plus Two Nucleoside (or One Nucleoside and One Nucleotide) Reverse-Transcriptase Inhibitors† | | | | |
|---|--|---|---|---|
| | NNRTI Component | Alternative NNRTI Component | NRTI Components | Alternative NRTI Component |
| Examples | Efavirenz (Sustiva): 600 mg once daily | Nevirapine (Viramune): 200 mg once daily for 14 days, then 200 mg twice daily | Zidovudine–lamivudine (Combivir): 300 mg and 150 mg twice daily as fixed-dose combination; or tenofovir–emtricitabine (Truvada): 300 mg and 200 mg once daily as fixed-dose combination | Abacavir–lamivudine (Epzi-com): 600 mg and 300 mg once daily as fixed-dose combination |
| Major side effects | Efavirenz: central nervous system symptoms (e.g., vivid dreams); rash; hepatotoxicity; teratogenic effects in first trimester‡ | Nevirapine: rash, hepatotoxicity, hypersensitivity syndrome; should be used with caution in women and men with CD4 cell counts of >250/mm ³ and >400/mm ³ , respectively, because of increased risk of hepatotoxicity | Zidovudine (Retrovir)§: headache, nausea, anemia, leukopenia; tenofovir (Viread)§: gastrointestinal symptoms, renal dysfunction; lamivudine (EpiVir) and emtricitabine (Emtriva)§: generally well tolerated | Abacavir (Ziagen)§: 5% incidence of hypersensitivity syndrome (fever, rash, gastrointestinal symptoms, respiratory symptoms), which may be fatal, especially on rechallenge |
| A Protease Inhibitor plus Two Nucleoside (or One Nucleoside and One Nucleotide) Reverse-Transcriptase Inhibitors† | | | | |
| | PI Component | Alternative PI Component¶ | NRTI Components | Alternative NRTI Component |
| Examples | Lopinavir–ritonavir (Kaletra): 400 mg and 100 mg twice daily or 800 mg and 200 mg once daily as fixed-dose combination | Atazanavir–ritonavir (Reyataz and Norvir): 300 mg and 100 mg once daily | Zidovudine–lamivudine: 300 mg and 150 mg twice daily as fixed-dose combination; or tenofovir–emtricitabine: 300 mg and 200 mg once daily as fixed-dose combination | Abacavir–lamivudine: 600 mg and 300 mg once daily as fixed-dose combination |
| Major side effects | Lopinavir–ritonavir: gastrointestinal symptoms; elevated liver-enzyme levels; hyperlipidemia; fat redistribution; insulin resistance | Atazanavir: increased indirect bilirubin levels; gastrointestinal symptoms; prolonged PR interval | Zidovudine§: headache, nausea, anemia, leukopenia; tenofovir§: gastrointestinal symptoms, renal dysfunction; can lower atazanavir levels unless latter is administered with low-dose ritonavir; lamivudine and emtricitabine§: generally well tolerated | Abacavir§: 5% incidence of hypersensitivity syndrome (fever, rash, gastrointestinal symptoms, respiratory symptoms), which may be fatal, especially on rechallenge |

* The regimens listed in this table were chosen to illustrate the selection of components of drug combinations that are based on nonnucleoside reverse-transcriptase inhibitors (NNRTI) and protease inhibitors (PI). Efficacy, toxicity, and simplicity of the regimens as demonstrated in clinical trials formed the basis of selection. This table is not intended to be comprehensive with respect to all possible initial combinations or to be a substitute for consensus guidelines; however, the regimens listed are concordant with these guidelines. NRTI denotes nucleoside or nucleotide reverse-transcriptase inhibitor. Data are from the Department of Health and Human Services¹² and Yeni et al.¹⁷

† Multiple drug interactions occur with nonnucleoside reverse-transcriptase inhibitors and protease inhibitors because of their metabolism by, and influence on, the CYP3A4 hepatic-enzyme system. All HIV and non-HIV medications prescribed for patients who take these drugs should be checked for possible interactions. Decreased bone mineral density in women and men may occur as a side effect of protease inhibitors or tenofovir, as a manifestation of underlying HIV disease, or both.

‡ Because of the potential for teratogenic effects, efavirenz is contraindicated during the first trimester of pregnancy and in women with child-bearing potential who are not using effective contraception.

§ All nucleoside or nucleotide reverse-transcriptase inhibitors carry a warning label concerning the risk of mitochondrial dysfunction, steatohepatitis, and lactic acidosis, which can be fatal. The risk varies among the drugs in this class; tenofovir, lamivudine, emtricitabine, and abacavir have a lower risk, in relative terms, than does stavudine (Zerif). The former also confer a lower risk of lipodystrophy than does stavudine.

¶ Other alternative protease inhibitor components include saquinavir (Invirase)–ritonavir, 1000 mg and 100 mg, twice daily and fosamprenavir (Lexiva)–ritonavir, 700 mg and 100 mg, twice daily or 1400 mg and 200 mg once daily.

respectively, at 48 weeks.⁴² Tolerance was a factor in these results, since there were more treatment discontinuations in the zidovudine–lamivudine group than in the tenofovir–emtricitabine group.

The basic alternative regimen is the combination of a ritonavir-boosted protease inhibitor (e.g., lopinavir, atazanavir, saquinavir, or fosamprenavir) and a dual nucleoside or nucleoside–nucleotide component, as described above (Table 4). At a dose of 100 to 200 mg once or twice daily, ritonavir does not have *in vivo* anti-HIV activity, but it acts to enhance the activity of the drug with which it is paired by inhibiting the hepatic CYP3A4-mediated metabolism of the latter.^{43,44} The pharmacokinetic profile of the protease inhibitor nelfinavir is not appreciably enhanced by ritonavir, and this drug has been shown to be less potent than the combination of lopinavir and ritonavir.⁴⁵

Protease inhibitors have been associated with a range of metabolic side effects, including the metabolic syndrome (hyperlipidemia, central fat accumulation, and insulin resistance), but the frequency with which they cause these abnormalities is variable. These metabolic derangements, along with those such as lipoatrophy and mitochondrial toxicity that are related to nucleoside analogues, have contributed to the rationale that the start of antiretroviral therapy should be deferred until it is clearly necessary. Cardiovascular risk is a concern. In a large, multicohort study, combination antiretroviral therapy was associated with a 26 percent increase in the risk of myocardial infarction per year of regimen exposure.¹¹ Atazanavir has the advantage of not inducing lipid-level elevations, but further study is needed to assess whether this advantage translates into reduced cardiovascular risk with this drug as compared with other protease inhibitors.

A third alternative regimen, involving triple nucleoside–nucleotide combinations, is no longer considered optimal for initial therapy. The combination of zidovudine, lamivudine, and abacavir confers reasonable viral suppression but is inferior to a regimen containing efavirenz.⁴⁶ A regimen of zidovudine, lamivudine, and tenofovir holds promise,⁴⁷ but data from randomized, controlled clinical trials are needed before it can be recommended unequivocally. Other triple nucleoside–nucleotide regimens (e.g., didanosine, lamivudine, and tenofovir and abacavir, lamivudine, and tenofovir) are associated with unacceptably high virologic failure rates and should not be used.^{12,17}

Once an antiretroviral regimen is begun, close support of the patient is mandatory, to help ensure maximum drug adherence, manage low-grade drug-related symptoms, watch for toxic effects of the drugs (including life-threatening hepatotoxicity and hypersensitivity reactions), and monitor virologic and immunologic responses. Clinical outcomes also have been directly linked to the level of adherence to antiretroviral therapy.⁴⁸ In the long term, continued support and close monitoring for metabolic toxic effects (including cardiovascular risks) are crucial.

AREAS OF UNCERTAINTY

Several questions remain unanswered with regard to antiretroviral therapy for established HIV infection. These include whether it is possible to improve potency or whether there is an irreducible reservoir of low-level viral replication that cannot be affected by current agents³⁷; what clinical role recently developed laboratory techniques, such as monitoring drug levels and viral replicative capacity during therapy,⁴⁹ have; how best to manage or prevent the metabolic toxic effects — hyperlipidemia, lipodystrophic syndromes, insulin resistance, lactic acidosis, and osteopenia — that are associated with antiretroviral therapy, underlying HIV infection, or both^{50,51}; and the optimal management of infection in patients who are also infected with hepatitis B virus, hepatitis C virus, or both.^{52,53} In addition, the role of new classes of antiretroviral drugs (such as chemokine-receptor blockers and integrase inhibitors) in initial therapy for HIV infection will need to be determined in clinical trials.

GUIDELINES FROM PROFESSIONAL SOCIETIES

Two major U.S. guidelines for the use of antiretroviral therapy have been developed and are routinely updated by the Department of Health and Human Services and the International AIDS Society–USA (IAS–USA).^{12,17} Primary care guidelines for the management of HIV infection have been published by the Infectious Diseases Society of America (IDSA)¹³ and the U.S. Public Health Service–IDSA has issued recommendations for the prevention of opportunistic infections.²⁵ The recommendations in this article are consistent with these guidelines. Other useful documents include guidelines developed by the IAS–USA for testing for HIV

drug resistance¹⁵; guidelines for treating opportunistic infections, recently updated by the CDC, the National Institutes of Health, the HIV Medicine Association, and the IDSA²⁴; guidelines developed by the Department of Health and Human Services for the treatment of pregnant women infected with HIV⁵⁴; and recommendations developed by the IAS-USA and the AIDS Clinical Trials Group for the management of metabolic complications.^{51,55}

CONCLUSIONS AND RECOMMENDATIONS

In patients with newly diagnosed HIV infection, the initial emphasis should be on counseling with regard to the disease process, limiting the risk of secondary transmission, ensuring that there is proper support for the patient, and building a trusting relationship between the patient and the caregiver. An otherwise healthy person with asymptomatic HIV infection and no coexisting illnesses, such as the woman described in the vignette, should be advised that decades of productive life, which can include intentional pregnancies if desired,⁵⁶ are possible with proper care. The woman in the vignette is at a disease stage (a CD4 cell count of 325 cells per cubic millimeter and a plasma HIV-1 RNA level of 60,000 copies per milliliter) at which routine vaccinations are indicated but at which prophylaxis against *P. jiroveci*, *T. gondii*, and *M. avium* complex

infections is not. Performing a genotypic HIV drug-resistance test is prudent, to be sure the patient is not infected with a drug-resistant virus. Given her CD4 cell count, initiating antiretroviral therapy should be discussed. If the patient were committed to therapy, I would recommend treatment at this point, as would most physicians. If there was doubt on the part of the patient or clinician about starting therapy, three to six months or more of observation, with serial measurement of CD4 cell counts and plasma HIV-1 RNA levels, would further inform the decision of when to start antiretroviral therapy. A regimen based on a nonnucleoside reverse-transcriptase inhibitor would be a reasonable first choice; I would start with efavirenz combined with the fixed-dose combination of tenofovir and emtricitabine. (Nevirapine is contraindicated, given this patient's CD4 cell count.) This combination would provide a potent, once-daily, and probably well-tolerated regimen involving a total of two pills. Effective contraception is needed, given the potential for teratogenic side effects with efavirenz. Close follow-up, to watch for side effects of therapy, provide ongoing support of drug adherence, and monitor plasma HIV-1 RNA levels and CD4 cell counts, is warranted, to optimize outcomes.

Supported by grants (AI46386, AI42848, AI48013, and AI41534) from the National Institutes of Health.

Dr. Hammer reports having received honoraria for consulting from Tibotec, Boehringer Ingelheim, Pfizer, and Progenics and research support from Merck.

REFERENCES

- Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. *N Engl J Med* 2000;342:921-9.
- Diagnoses of HIV/AIDS — 32 states, 2000–2003. *MMWR Morb Mortal Weekly Rep* 2004;53:1106-10.
- Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1998;338:853-60.
- CDC posts new HIV testing, referral guidelines. *AIDS Alert* 2002;17(1):2, 8-10.
- Paltiel AD, Weinstein MC, Kimmel AD, et al. Expanded screening for HIV in the United States — an analysis of cost-effectiveness. *N Engl J Med* 2005;352:586-95.
- Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. *N Engl J Med* 2005;352:570-85.
- Bulterys M, Jamieson DJ, O'Sullivan MJ, et al. Rapid HIV-1 testing during labor: a multicenter study. *JAMA* 2004;292:219-23.
- Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. *Lancet* 2005;365:1031-8.
- Goulder PJ, Walker BD. HIV-1 superinfection — a word of caution. *N Engl J Med* 2002;347:756-8.
- Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. *Fam Plann Perspect* 1999;31:272-9.
- Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med* 2003;349:1993-2003. [Erratum, *N Engl J Med* 2004;350:955.]
- Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Panel on clinical practices for treatment of HIV infection (Department of Health and Human Services). (Available at <http://aidsinfo.nih.gov/guidelines/adult>.)
- Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis* 2004;39:609-29.
- Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. *Ann Intern Med* 1997;126:946-54.
- Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. *Clin Infect Dis* 2003;37:113-28.
- Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. *N Engl J Med* 2002;347:385-94.
- Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. *JAMA* 2004;292:251-65.
- Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet* 2002;360:119-29. [Erratum, *Lancet* 2002;360:1178.]

19. Laine C, Markson LE, McKee LJ, Hauck WW, Fanning TR, Turner BJ. The relationship of clinic experience with advanced HIV and survival of women with AIDS. *AIDS* 1998; 12:417-24.
20. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. *Ann Intern Med* 1996;124:633-42.
21. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of *Pneumocystis carinii* pneumonia among men infected with human immunodeficiency virus type 1. *N Engl J Med* 1990;322:161-5.
22. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. *N Engl J Med* 1995;332:693-9.
23. Masur H. Recommendations on prophylaxis and therapy for disseminated *Mycobacterium avium* complex disease in patients infected with the human immunodeficiency virus. *N Engl J Med* 1993;329:898-904.
24. Treating opportunistic infections among HIV-infected adults and adolescents. *MMWR Morb Mortal Weekly Rep* 2004;53(RR-15): 1-112.
25. Guidelines for preventing opportunistic infections among HIV-infected persons. *MMWR Morb Mortal Weekly Rep* 2002; 51(RR-08):1-46.
26. Opravil M, Ledergerber B, Furrer H, et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count >350 × 10⁶/l. *AIDS* 2002; 16:1371-81.
27. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. *Ann Intern Med* 2003;138:620-6.
28. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. *J Infect Dis* 2003; 188:1659-65.
29. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. *AIDS* 2001;15:2251-7.
30. Sterling TR, Chaisson RE, Moore RD. Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm³: disease progression, treatment durability, and drug toxicity. *Clin Infect Dis* 2003;36:812-5.
31. Ahdieh-Grant L, Yamashita TE, Phair JP, et al. When to initiate highly active antiretroviral therapy: a cohort approach. *Am J Epidemiol* 2003;157:738-46.
32. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. *JAMA* 2001;286:2568-77.
33. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. *JAMA* 2001;286: 2560-7.
34. Wood E, Hogg RS, Yip B, Harrigan PR, Montaner JS. Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy. *Rev Invest Clin* 2004;56:232-6.
35. Chun TW, Justement JS, Lempicki RA, et al. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. *Proc Natl Acad Sci U S A* 2003;100: 1908-13.
36. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. *Nat Med* 1999;5:512-7.
37. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. *JAMA* 2005;293:817-29.
38. Nickle DC, Jensen MA, Shriner D, et al. Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. *J Virol* 2003;77:5540-6.
39. Parera M, Ibanez A, Clotet B, Martinez MA. Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy. *J Infect Dis* 2004;189:1444-51.
40. Zhang L, Chung C, Hu BS, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. *J Clin Invest* 2000;106:839-45.
41. Bartlett JA, Fath MJ, DeMasi R, et al. An updated meta-analysis of triple combination therapy in antiretroviral-naïve HIV-infected adults. Presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 22–25, 2005. abstract.
42. Pozniak AL, Gallant JE, DeJesus E, et al. Superior outcome for tenofovir DF, emtricitabine and efavirenz compared to fixed dose zidovudine/lamivudine and efavirenz in antiretroviral naïve patients. Presented at the 3rd IAS Conference on Pathogenesis and Treatment, Rio de Janeiro, July 24–27, 2005. abstract.
43. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. *HIV Med* 2001;2:105-13.
44. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. *J Antimicrob Chemother* 2004;53:4-9.
45. Walmsley S, Bernstein B, King M, et al. Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection. *N Engl J Med* 2002;346:2039-46.
46. Gulick RM, Ribbaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. *N Engl J Med* 2004;350:1850-61.
47. Kaleebu P, DART Trial Team. 48 Week virological response to a triple nucleoside/nucleotide analog regimen in adults with HIV infection in Africa within the DART trial. Presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 24–27, 2005. abstract.
48. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. *AIDS* 2001;15:1181-3.
49. Deeks SG, Wrinn T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. *N Engl J Med* 2001;344: 472-80.
50. Currier J. Management of metabolic complications of therapy. *AIDS* 2002;16: Suppl 4:S171-S176.
51. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. *J Acquir Immune Defic Syndr* 2002;31:257-75.
52. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. *Clin Infect Dis* 2004;38:Suppl 2:S98-S103.
53. Plosker GL, Keating GM. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C virus and HIV coinfection. *Drugs* 2004;64:2823-43.
54. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Public Health Service Task Force and Perinatal HIV Guidelines Working Group. (Accessed September 30, 2005, at http://aidsinfo.nih.gov/guidelines/perinatal/PER_022405.pdf.)
55. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. *Clin Infect Dis* 2003;37:613-27.
56. Ohl J, Partisani M, Wittemer C, et al. Assisted reproduction techniques for HIV serodiscordant couples: 18 months of experience. *Hum Reprod* 2003;18:1244-9.

Copyright © 2005 Massachusetts Medical Society.